JPWO2023115033A5 - - Google Patents
Info
- Publication number
- JPWO2023115033A5 JPWO2023115033A5 JP2024536179A JP2024536179A JPWO2023115033A5 JP WO2023115033 A5 JPWO2023115033 A5 JP WO2023115033A5 JP 2024536179 A JP2024536179 A JP 2024536179A JP 2024536179 A JP2024536179 A JP 2024536179A JP WO2023115033 A5 JPWO2023115033 A5 JP WO2023115033A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- cancer
- taa
- antigen
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163265521P | 2021-12-16 | 2021-12-16 | |
| US63/265,521 | 2021-12-16 | ||
| PCT/US2022/081862 WO2023115033A2 (en) | 2021-12-16 | 2022-12-16 | Use of dual cytokine fusion proteins comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024546999A JP2024546999A (ja) | 2024-12-26 |
| JPWO2023115033A5 true JPWO2023115033A5 (https=) | 2025-12-19 |
| JP2024546999A5 JP2024546999A5 (https=) | 2025-12-19 |
Family
ID=86773657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024536179A Pending JP2024546999A (ja) | 2021-12-16 | 2022-12-16 | Ｉｌ－１０を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性ｔ細胞エンゲージャー |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230210953A1 (https=) |
| EP (1) | EP4447996A4 (https=) |
| JP (1) | JP2024546999A (https=) |
| KR (1) | KR20240161974A (https=) |
| CN (1) | CN118695868A (https=) |
| AU (1) | AU2022413694A1 (https=) |
| CA (1) | CA3240977A1 (https=) |
| IL (1) | IL313588A (https=) |
| MX (1) | MX2024007404A (https=) |
| WO (1) | WO2023115033A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7641912B2 (ja) | 2019-04-19 | 2025-03-07 | シナーキン・ファーマ・ベスローテン・フエンノートシャップ | Ｉｌ１３を含む融合タンパク質 |
| CA3186753A1 (en) * | 2020-07-20 | 2022-01-27 | John Mumm | Dual cytokine fusion proteins comprising il-10 |
| CN118900697A (zh) * | 2022-02-22 | 2024-11-05 | 德卡生物科学公司 | 使用白细胞介素减轻双特异性t细胞接合器或嵌合抗原受体t细胞介导的细胞因子释放综合征的方法 |
| CN117327184B (zh) * | 2023-12-01 | 2024-03-05 | 赛奥斯博生物科技(北京)有限公司 | 一种靶向msln的嵌合抗原受体及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989867A (en) * | 1996-09-23 | 1999-11-23 | Knappe; Andrea | DNA encoding IL-10-like homologue; related reagents |
| JP4793971B2 (ja) * | 1999-08-09 | 2011-10-12 | メルク パテント ゲーエムベーハー | 複合サイトカイン−抗体複合体 |
| WO2018156791A1 (en) * | 2017-02-22 | 2018-08-30 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
| JP2022524018A (ja) * | 2019-03-06 | 2022-04-27 | デカ バイオサイエンシーズ， インコーポレイテッド | Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 |
| CA3186753A1 (en) * | 2020-07-20 | 2022-01-27 | John Mumm | Dual cytokine fusion proteins comprising il-10 |
-
2022
- 2022-12-16 JP JP2024536179A patent/JP2024546999A/ja active Pending
- 2022-12-16 EP EP22908772.1A patent/EP4447996A4/en active Pending
- 2022-12-16 WO PCT/US2022/081862 patent/WO2023115033A2/en not_active Ceased
- 2022-12-16 CA CA3240977A patent/CA3240977A1/en active Pending
- 2022-12-16 AU AU2022413694A patent/AU2022413694A1/en active Pending
- 2022-12-16 US US18/067,535 patent/US20230210953A1/en active Pending
- 2022-12-16 MX MX2024007404A patent/MX2024007404A/es unknown
- 2022-12-16 CN CN202280091741.8A patent/CN118695868A/zh active Pending
- 2022-12-16 IL IL313588A patent/IL313588A/en unknown
- 2022-12-16 KR KR1020247023470A patent/KR20240161974A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Herrera et al. | Bispecific antibodies: advancing precision oncology | |
| Fabian et al. | The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy | |
| Goebeler et al. | Bispecific and multispecific antibodies in oncology: opportunities and challenges | |
| Tapia-Galisteo et al. | Bi-and trispecific immune cell engagers for immunotherapy of hematological malignancies | |
| Pinto et al. | Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers | |
| Huehls et al. | Bispecific T‐cell engagers for cancer immunotherapy | |
| Xu et al. | Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody | |
| Gargett et al. | The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells | |
| IL313588A (en) | Use of dual cytokine fusion proteins comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer | |
| Thakur et al. | “NextGen” biologics: bispecific antibodies and emerging clinical results | |
| JP2021526136A (ja) | 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法 | |
| AU2018250148B2 (en) | Treatment using chimeric receptor T cells incorporating optimized polyfunctional T cells | |
| Urbanska et al. | Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells | |
| JP2015527070A5 (https=) | ||
| WO2023081705A1 (en) | Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies | |
| KR20240008345A (ko) | T 세포 재유도 치료제 및 항-cd44 치료제를 포함하는 조성물 | |
| Rosenzweig et al. | Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis | |
| JP2024016200A (ja) | キメラ抗原受容体療法のｔ細胞の増殖動態及びその使用 | |
| Koch et al. | Recombinant antibodies to arm cytotoxic lymphocytes in cancer immunotherapy | |
| Wang et al. | An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers | |
| Nikkhoi et al. | Natural killer cell engagers for cancer immunotherapy | |
| Zarnani et al. | Monoclonal antibodies for cancer immunotherapy | |
| Cortes-Hernandez et al. | Chimeric antigen receptor (CAR) T cell therapy for cancer. Challenges and opportunities: An overview | |
| Long et al. | Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma | |
| Hambach et al. | Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors |